Perspective Therapeutics (AAJ0) Stock Forecast & Price Target

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AAJ0 Analyst Ratings

Strong Buy

11 Buy

1 Hold

0 Sell

Based on 12 analysts giving stock ratings to

Perspective

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AAJ0 Stock 12 Month Forecast

Average Price Target

€10.85

▲(306.42% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for Perspective Therapeutics in the last 3 months. The average price target is €10.85 with a high forecast of €16.03 and a low forecast of €4.45. The average price target represents a 306.42% change from the last price of €2.67.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","17":"€17","4.25":"€4.25","8.5":"€8.5","12.75":"€12.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16.03403496,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€16.03</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10.851316589090908,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€10.85</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.4538986,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€4.45</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4.25,8.5,12.75,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.314,3.3693873046153846,4.424774609230769,5.480161913846153,6.535549218461538,7.590936523076923,8.646323827692306,9.701711132307691,10.757098436923076,11.812485741538461,12.867873046153846,13.92326035076923,14.978647655384615,{"y":16.03403496,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.314,2.970716660699301,3.6274333213986014,4.284149982097902,4.940866642797203,5.597583303496504,6.254299964195804,6.911016624895105,7.5677332855944055,8.224449946293706,8.881166606993007,9.537883267692308,10.194599928391607,{"y":10.851316589090908,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.314,2.4786075846153848,2.643215169230769,2.8078227538461538,2.9724303384615385,3.1370379230769228,3.3016455076923075,3.466253092307692,3.630860676923077,3.795468261538461,3.960075846153846,4.12468343076923,4.289291015384615,{"y":4.4538986,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.12,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.2,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.91,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.22,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.92,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.26,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.52,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.248,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.284,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.098,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.65,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.862,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.314,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€16.03

Average Price Target€10.85

Lowest Price Target€4.45

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

David Lebowitz

BMO Capital

€9.8

Buy

266.99%

Upside

Reiterated

10/20/26

Lebowitz Reiterates Buy on Perspective Therapeutics, Keeps Price Target at $11 on Advancing Radioligand Pipeline

Alec Stranahan

Bank of America Securities

€4.45

Hold

66.81%

Upside

Reiterated

10/19/26

Perspective Therapeutics (CATX) Gets a Hold from Bank of America Securities

Leonid Timashev

RBC Capital

€12.47

Buy

367.08%

Upside

Reiterated

10/16/26

Analysts Conflicted on These Healthcare Names: Perspective Therapeutics (NYSE MKT: CATX), Bristol-Myers Squibb (NYSE: BMY) and Incyte (NASDAQ: INCY)

Unknown Analyst

Wedbush

Not Ranked

Wedbush

€9.8

Buy

266.99%

Upside

Reiterated

10/13/26

Perspective Therapeutics (CATX) Receives a Buy from Wedbush

Gregory Renza

Truist Financial

€9.8

Buy

266.99%

Upside

Reiterated

10/13/26

Analysts Are Bullish on These Healthcare Stocks: Nurix Therapeutics (NRIX), Perspective Therapeutics (CATX)

David Dai

UBS

€7.13

Buy

166.90%

Upside

Reiterated

10/02/26

Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (NYSE MKT: CATX) and Integra Lifesciences (NASDAQ: IART)

Andy Hsieh

William Blair

―

Buy

―

Initiated

09/18/26

Perspective Therapeutics initiated with an Outperform at William BlairPerspective Therapeutics initiated with an Outperform at William Blair

Justin Walsh

JonesTrading

€16.03

Buy

500.53%

Upside

Reiterated

08/14/26

Perspective Therapeutics Earns Buy Rating as Justin Walsh Reaffirms $18 Price Target on Strength of Pb-212 Pipeline and Upcoming Phase III Program

Oliver McCammon

LifeSci Capital

€13.36

Buy

400.44%

Upside

Reiterated

08/11/26

Analysts Offer Insights on Healthcare Companies: Atossa Therapeutics (NASDAQ: ATOS), Corvus Pharmaceuticals (NASDAQ: CRVS) and Perspective Therapeutics (NYSE MKT: CATX)

Jeet Mukherjee

BTIG

€12.47

Buy

367.08%

Upside

Reiterated

08/11/26

Perspective Therapeutics: Advancing Pipeline, Strong Fundamentals Support Buy Rating and Unchanged $14 Price Target

Jeff Jones

Oppenheimer

€11.58

Buy

333.71%

Upside

Reiterated

08/11/26

Perspective Therapeutics (CATX) Gets a Buy from Oppenheimer

Biren Amin

Piper Sandler

€14.25→€12.47

Buy

367.08%

Upside

Assigned

08/11/26

Piper Sandler Sticks to Their Buy Rating for Perspective Therapeutics (CATX)

Robert Burns

H.C. Wainwright

€11.58

Buy

333.71%

Upside

Reiterated

06/01/26

H.C. Wainwright Reaffirms Their Buy Rating on Perspective Therapeutics (CATX)

Yuan Zhi

B. Riley Securities

€9.8→€11.58

Buy

333.71%

Upside

Assigned

03/18/26

Perspective Therapeutics price target raised to $13 from $11 at B. RileyPerspective Therapeutics price target raised to $13 from $11 at B. Riley

Rajan Sharma

Goldman Sachs

―

Buy

―

Reiterated

02/17/26

Buy Rating on Perspective Therapeutics (CATX) Driven by Differentiated Radiopharmaceutical Platform and Undervalued Long-Term Upside

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

David Lebowitz

BMO Capital

€9.8

Buy

266.99%

Upside

Reiterated

10/20/26

Lebowitz Reiterates Buy on Perspective Therapeutics, Keeps Price Target at $11 on Advancing Radioligand Pipeline

Alec Stranahan

Bank of America Securities

€4.45

Hold

66.81%

Upside

Reiterated

10/19/26

Perspective Therapeutics (CATX) Gets a Hold from Bank of America Securities

Leonid Timashev

RBC Capital

€12.47

Buy

367.08%

Upside

Reiterated

10/16/26

Analysts Conflicted on These Healthcare Names: Perspective Therapeutics (NYSE MKT: CATX), Bristol-Myers Squibb (NYSE: BMY) and Incyte (NASDAQ: INCY)

Unknown Analyst

Wedbush

Not Ranked

Wedbush

€9.8

Buy

266.99%

Upside

Reiterated

10/13/26

Perspective Therapeutics (CATX) Receives a Buy from Wedbush

Gregory Renza

Truist Financial

€9.8

Buy

266.99%

Upside

Reiterated

10/13/26

Analysts Are Bullish on These Healthcare Stocks: Nurix Therapeutics (NRIX), Perspective Therapeutics (CATX)

David Dai

UBS

€7.13

Buy

166.90%

Upside

Reiterated

10/02/26

Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (NYSE MKT: CATX) and Integra Lifesciences (NASDAQ: IART)

Andy Hsieh

William Blair

―

Buy

―

Initiated

09/18/26

Perspective Therapeutics initiated with an Outperform at William BlairPerspective Therapeutics initiated with an Outperform at William Blair

Justin Walsh

JonesTrading

€16.03

Buy

500.53%

Upside

Reiterated

08/14/26

Perspective Therapeutics Earns Buy Rating as Justin Walsh Reaffirms $18 Price Target on Strength of Pb-212 Pipeline and Upcoming Phase III Program

Oliver McCammon

LifeSci Capital

€13.36

Buy

400.44%

Upside

Reiterated

08/11/26

Analysts Offer Insights on Healthcare Companies: Atossa Therapeutics (NASDAQ: ATOS), Corvus Pharmaceuticals (NASDAQ: CRVS) and Perspective Therapeutics (NYSE MKT: CATX)

Jeet Mukherjee

BTIG

€12.47

Buy

367.08%

Upside

Reiterated

08/11/26

Perspective Therapeutics: Advancing Pipeline, Strong Fundamentals Support Buy Rating and Unchanged $14 Price Target

Jeff Jones

Oppenheimer

€11.58

Buy

333.71%

Upside

Reiterated

08/11/26

Perspective Therapeutics (CATX) Gets a Buy from Oppenheimer

Biren Amin

Piper Sandler

€14.25→€12.47

Buy

367.08%

Upside

Assigned

08/11/26

Piper Sandler Sticks to Their Buy Rating for Perspective Therapeutics (CATX)

Robert Burns

H.C. Wainwright

€11.58

Buy

333.71%

Upside

Reiterated

06/01/26

H.C. Wainwright Reaffirms Their Buy Rating on Perspective Therapeutics (CATX)

Yuan Zhi

B. Riley Securities

€9.8→€11.58

Buy

333.71%

Upside

Assigned

03/18/26

Perspective Therapeutics price target raised to $13 from $11 at B. RileyPerspective Therapeutics price target raised to $13 from $11 at B. Riley

Rajan Sharma

Goldman Sachs

―

Buy

―

Reiterated

02/17/26

Buy Rating on Perspective Therapeutics (CATX) Driven by Differentiated Radiopharmaceutical Platform and Undervalued Long-Term Upside

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

PTGXProtagonist Therapeutics

SIBNSI-Bone

IMUXImmunic

MDWDMediwound

HROWHarrow Health

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Perspective Therapeutics

3 Months

Yuan ZhiB. Riley Securities

Success Rate

5/11 ratings generated profit

Average Return

+16.14%

Copying Yuan Zhi's trades and holding each position for 3 Months would result in 45.45% of your transactions generating a profit, with an average return of +16.14% per trade.

1 Year

Jeff JonesOppenheimer

Success Rate

8/24 ratings generated profit

Average Return

+0.51%

Copying Jeff Jones's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of +0.51% per trade.

2 Years

Gregory RenzaTruist Financial

Success Rate

2/15 ratings generated profit

Average Return

-40.05%

Copying Gregory Renza's trades and holding each position for 2 Years would result in 13.33% of your transactions generating a profit, with an average return of -40.05% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AAJ0 Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AAJ0 has received 20 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. AAJ0 average Analyst price target in the past 3 months is 10.85.

Each month's total comprises the sum of three months' worth of ratings.

AAJ0 Financial Forecast

AAJ0 Earnings Forecast

Next quarter’s earnings estimate for AAJ0 is -€0.21 with a range of -€0.27 to -€0.17. The previous quarter’s EPS was -€0.19. AAJ0 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year AAJ0 has Performed in-line its overall industry.

AAJ0 Sales Forecast

Next quarter’s sales forecast for AAJ0 is €53.51K with a range of €0.00 to €144.13K. The previous quarter’s sales results were €69.91K. AAJ0 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year AAJ0 has Performed in-line its overall industry.

AAJ0 Stock Forecast FAQ

What is DE:AAJ0’s average 12-month price target, according to analysts?

Based on analyst ratings, Perspective Therapeutics’s 12-month average price target is 10.85.

What is DE:AAJ0’s upside potential, based on the analysts’ average price target?

Perspective Therapeutics has 306.42% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Perspective Therapeutics a Buy, Sell or Hold?

Perspective Therapeutics has a consensus rating of Strong Buy, which is based on 11 buy ratings, 1 hold ratings and 0 sell ratings.

What is Perspective Therapeutics’s share price target?

The average share price target for Perspective Therapeutics is 10.85. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €16.03 ,and the lowest forecast is €4.45. The average share price target represents 306.42% Increase from the current price of €2.67.

What do analysts say about Perspective Therapeutics?

Perspective Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of Perspective Therapeutics?

To buy shares of DE:AAJ0, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Perspective Therapeutics (AAJ0) Stock Forecast & Price Target

AAJ0 Analyst Ratings

AAJ0 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Perspective Therapeutics

AAJ0 Analyst Recommendation Trends

AAJ0 Financial Forecast

AAJ0 Earnings Forecast

AAJ0 Sales Forecast

AAJ0 Stock Forecast FAQ

Detailed List of Analyst Forecasts